Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients.
Ontology highlight
ABSTRACT: Breast cancer has become the most common cancer in the US and worldwide. While advances in early detection and treatment have resulted in a 40% reduction in breast cancer mortality, this reduction has not been achieved uniformly among racial groups. A large percentage of non-metastatic breast cancer mortality is related to the cardiovascular effects of breast cancer therapies. These effects appear to be more prevalent among patients from historically marginalized racial/ethnic backgrounds, such as African American and Hispanic individuals. Anthracyclines, particularly doxorubicin and daunorubicin, are the first-line treatments for breast cancer patients. However, their use is limited by their dose-dependent and cumulative cardiotoxicity, manifested by cardiomyopathy, ischemic heart disease
SUBMITTER: Balaji S
PROVIDER: S-EPMC10452913 | biostudies-literature | 2023 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA